ret-ah-TROO-tide
A triple-action weight loss molecule targeting three gut hormone receptors at once — the next evolution beyond tirzepatide.
Also known as: LY3437943, Triple G
Last reviewed: April 2026
Retatrutide activates three receptors simultaneously: GLP-1 (appetite), GIP (metabolism), and glucagon (fat burning). It's the 'triple agonist' — one step beyond tirzepatide's dual action. Phase 2 trials showed up to 24% weight loss at 48 weeks, making it potentially the most effective weight loss molecule yet studied.
Once-weekly injection
Frequency
Once weekly
Pain Level
●○○ Minimal
Self-Administered
Yes — at home
Typical Range
1mg – 12mg (titrated)
Month 1–2
Dose titration. Appetite reduction begins.
Month 6
Significant weight loss — Phase 2 trials showed ~17% at 24 weeks.
Month 12
Up to 24% body weight loss in trials.
Overall: Mild
Nausea
Most common side effect, improves with titration.
Decreased appetite
Intended effect.
Diarrhea
GI effects common with GLP-1 agonists.
• Thyroid cancer history
• MEN 2 syndrome
• Pancreatitis history
• Pregnancy
• Insulin — dose adjustment needed
• Oral medications — absorption may be delayed
Pregnancy: Do not use during pregnancy.
Semaglutide: 1 receptor (GLP-1). Tirzepatide: 2 receptors (GLP-1 + GIP). Retatrutide: 3 receptors (GLP-1 + GIP + glucagon). Each generation shows more weight loss.
Tirzepatide
A dual-action weight loss medication that mimics two gut hormones at once for enhanced metabolic results.
Semaglutide
A medication that reduces appetite and helps your body lose weight by mimicking a natural gut hormone.
We don't currently offer this peptide — but we have protocols for similar goals.
Coming Soon →This is a compounded medication prescribed off-label. It has not been FDA-approved for the uses described. All prescribing decisions are made by your independent licensed provider.